Neuroendocrine Cancer

Access ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.

Chris Verslype explains that the management of gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) should rely on pathology findings on how well differentiated the tumour is, and the level of proliferation marker Ki67. He describes treatment options and follow-up plan recommendations according to disease staging.

More ESMO Videos from the Neuroendocrine Tumours track